Navigation Links
Spectrum Pharmaceuticals to Present at the 2007 BIOCOM Investor Conference
Date:10/31/2007

IRVINE, Calif., Oct. 31 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc., (Nasdaq: SPPI) announced today that it will present an overview of the Company on Thursday, November 1, 2007, at 2:00 p.m. Pacific, at the BIOCOM Investor Conference, being held at the Marriott Del Mar in San Diego, California. Spectrum's presentation will be held in Room 3 of the Rancho Santa Fe Ballroom.

The live webcast of Spectrum's presentation will be available at http://www.spectrumpharm.com. Replays will be available for 30 days.

About Spectrum Pharmaceuticals

Spectrum Pharmaceuticals acquires, develops and commercializes a diversified portfolio of oncology drug candidates that meet critical health challenges for which there are few other treatment options. The company's pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as at-home chemotherapy and new treatment regimens for refractory disease. For more information, please visit our website at http://www.spectrumpharm.com.

Forward-looking statement -- This press release may contain forward- looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements include but are not limited to statements that relate to our business and its future, Spectrum's ability to identify, acquire, develop and commercialize its portfolio of drug candidates, the Company's promising pipeline, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates, may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the FDA, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of revenues, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.

COMPANY CONTACTS

Russell Skibsted

SVP & Chief Business Officer

Paul Arndt

Manager, Investor Relations

949-788-6700

MEDIA CONTACT

Susan Neath

Porter Novelli Life Sciences

619-849-6007


'/>"/>
SOURCE Spectrum Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Tigecycline – New Generation Tetracycline With Broad Spectrum Antibacterial Activit
2. Simple Eye Movement Test For Early Detection Of Fetal Alcohol Spectrum Disorder
3. Lack Of Social Skills Linked To Autism Spectrum Disorder (ASD)
4. Broad Spectrum Antibiotic Available for Antibiotic Resistant Bacteria
5. Fetal Alcohol Spectrum Disorder in Children Can Be Diagnosed With Eye Movement Tests
6. Younger Siblings of Children With Autism Spectrum Disorders Score Low
7. Bipolar Spectrum Disorder may Be Under-recognized for Spectrum Disorder: Study
8. Supply of Radiopharmaceuticals Hampered by Attacks
9. FDA approves Watson Pharmaceuticals Oxytrol patch
10. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
11. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... Bellus Medical, ... latest innovation in the delivery of Platelet Rich Plasma (PRP). PRP systems are ... management, to accelerate tissue synthesis and provide a faster and more efficient healing ...
(Date:2/22/2017)... Athens, GA (PRWEB) , ... February 22, 2017 , ... ... Feb. 25 and 26 event in Athens, Georgia. , A shift from Super-Sod’s simple ... made in Georgia. , For the booth, grass seed plant manager Chris Roquemore constructed ...
(Date:2/22/2017)... ... February 22, 2017 , ... In ... many different solutions on the market, it is easy to start feeling frustrated ... Locksmith offers a complimentary security consultation. , Home Security Hardware Choices, There ...
(Date:2/21/2017)... Australia (PRWEB) , ... February 22, 2017 , ... Author ... it is valuable for every household and family to know all about it for ... publishing world with the release of “ Detox, Digestive and Wellness Solutions ” (published ...
(Date:2/21/2017)... ... February 21, 2017 , ... As recently as 2015, rhinoplasty was one of ... of Plastic Surgeons. Some patients want to make a change in the appearance of ... their breathing ability. The team at usrhinoplasty.org is expanding its article database ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... Research and Markets has announced the addition of ... report to their offering. ... Dermatological conditions are one of the ... the US population suffers from at least one active skin ... market has remained saturated with established and generic products. However, ...
(Date:2/22/2017)... , Feb. 22, 2017   Protein Sciences Corporation ... Flublok® Influenza Vaccine , announced today that they ... Influenza Vaccine Introduction (PIVI) and the Mongolian Ministry of ... of the flu.  The doses of Flublok have been ... Mongolia for health care workers, pregnant women, ...
(Date:2/22/2017)... February 22, 2017 A research report by ... America and the continuously changing landscape of the legal ... in the North America , a 30% increase ... to $21.6 billion by the year 2021 representing a 26 percent ... the United States and Canada ...
Breaking Medicine Technology: